Floatz logo

Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes

EBV Associated Lymphoma

Nantes University HospitalCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the EBV Associated Lymphoma cohort.

Asset / SponsorPhaseRating
Tabelecleucel
Pierre Fabre Medicament
Phase 3BB
Valganciclovir
Viracta Therapeutics, Inc.
Phase 2B
Hydroxyurea
University of Miami
Phase 2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Miami
Phase 2CCC
Arginine Butyrate
HemaQuest Pharmaceuticals Inc.
Phase 2CCC

View all 17 →

Same molecule, other indications

Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes is also rated in:

plasma cell myelomaDormant
B
Indicative ·
57 / 100
View asset →
leukemiaDormant
CCC
Indicative ·
55 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →